Home / Industry News / Clinical Trial Results from MyoKardia’s Phase 2 PIONEER-HCM Study of Mavacamten Published in the Annals of Internal Medicine

 

Mavacamten is Being Developed to Treat the Most Common Inherited Form of Heart Disease, Hypertrophic Cardiomyopathy, for which No Targeted Medical Therapies Exist Twelve-week Treatment with Mavacamten Demonstrated Reductions in Obstruction and Improvements in Patient Symptoms and Function

Learnings from Phase 2 Trial Informed and Guided Design of the Current Phase 3 EXPLORER-HCM Pivotal Trial SOUTH SAN FRANCISCO, Calif., April 30, 2019

MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today announced the publication of results from the company’s Phase 2 PIONEER-HCM study of mavacamten in an upcoming issue of the Annals of Internal Medicine. A copy of the article, “Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy” is now available online at the following link:  http://annals.org/aim/article/doi/10.7326/M18-3016

 

Share This